Johnson & Johnson Strengthens CNS Portfolio with CAPLYTA FDA Nod
TITUSVILLE, NEW JERSEY, April 27, 2026 Johnson & Johnson has received U.S. Food and Drug Administration (FDA) approval for...
CNS Drugs
Advertisement
DemeRx Gains FDA IND Clearance for DMX-1001 in AUD
Miami, Florida, USA – April 23, 2026 DemeRx announced that the U.S. Food and Drug Administration (FDA) has accepted...
Alzamend Reports Phase II AL001 Brain Data Gains
ATLANTA, United States, April 7, 2026 Alzamend Neuro, Inc. announced encouraging pharmacodynamic data from its Phase II clinical trial...
GH Research GH001 Shows Strong TRD Clinical Results
DUBLIN, Ireland, March 25, 2026 GH Research has announced the peer-reviewed publication of Phase 2b clinical results for GH001...
Advertisement
